Characterization of the steric defense of the HIV-1 gp41 N-trimer region

Protein Science

Volumn 17, Issue 12, 2008, Pages 2091-2100

  Eckert, Debra M ^a   Shi, Yu ^a   Kim, Sunghwan ^a   Welch, Brett D ^a   Kang, Eunchai ^a   Poff, Emily S ^a   Kay, Michael S ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Gp41 N trimer; Gp41 pocket; Prehairpin intermediate; Steric block

Indexed keywords

C PEPTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY D5; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; STEREOCHEMISTRY; STEREOSPECIFICITY;

HIV ENVELOPE PROTEIN GP41; HUMANS; KINETICS; MEMBRANE FUSION; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SURFACE PLASMON RESONANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 56749185286     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.038273.108     Document Type: Article

References (41)

1. Binley, J.M., Sanders, R.W., Clas, B., Schuelke, N., Master, A., Guo, Y., Kajumo, F., Anselma, D.J., Maddon, P.J., Olson, W.C., et al. 2000. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74: 627-643.
2. Chan, D.C., Fass, D., Berger, J.M., and Kim, P.S. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
3. Chen, B.K., Saksela, K., Andino, R., and Baltimore, D. 1994. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J. Virol. 68: 654-660.
4. Choe, H., Li, W., Wright, P.L., Vasilieva, N., Venturi, M., Huang, C.C., Grundner, C., Dorfman, T., Zwick, M.B., Wang, L., et al. 2003. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114: 161-170.
5. Connor, R.I., Chen, B.K., Choe, S., and Landau, N.R. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206: 935-944.
6. Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Di Marzio, P., Marmon, S., Sutton, R.E., Hill, C.M., et al. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661-666.
7. Eckert, D.M. and Kim, P.S. 2001. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70: 777-810.
8. Edelhoch, H. 1967. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6: 1948-1954.
9. Furuta, R.A., Wild, C.T., Weng, Y., and Weiss, C.D. 1998. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5: 276-279.
10. Golding, H., Zaitseva, M., de Rosny, E., King, L.R., Manischewitz, J., Sidorov, I., Gorny, M.K., Zolla-Pazner, S., Dimitrov, D.S., and Weiss, C.D. 2002. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J. Virol. 76: 6780-6790.
11. Hamburger, A.E., Kim, S., Welch, B.D., and Kay, M.S. 2005. Steric accessibility of the HIV-1 gp41 N-trimer region. J. Biol. Chem. 280: 12567-12572.
12. Haynes, B.F. and Montefiori, D.C. 2006. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5: 579-595.
13. He, J., Choe, S., Walker, R., Di Marzio, P., Morgan, D.O., and Landau, N.R. 1995. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69: 6705-6711.
14. He, Y., Vassell, R., Zaitseva, M., Nguyen, N., Yang, Z., Weng, Y., and Weiss, C.D. 2003. Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J. Virol. 77: 1666-1671.
15. Henderson, H.I. and Hope, T.J. 2006. The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infection. Virol. J. 3: 36. doi: 10.1186/11743-422X-3-36.
16. Jiang, S., Lin, K., Strick, N., and Neurath, A.R. 1993. HIV-1 inhibition by a peptide. Nature 365: 113. doi: 10.1038/365113a0.
17. Kim, S., Pang, H.B., and Kay, M.S. 2008. Peptide mimic of the HIV envelope gp120-gp41 interface. J. Mol. Biol. 376: 786-797.
18. Kwong, P.D., Wyatt, R., Robinson, J., Sweet, R.W., Sodroski, J., and Hendrickson, W.A. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659.
19. Labrijn, A.F., Poignard, P., Raja, A., Zwick, M.B., Delgado, K., Franti, M., Binley, J., Vivona, V., Grundner, C., Huang, C.C., et al. 2003. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77: 10557-10565.
20. Landau, N.R. and Littman, D.R. 1992. Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J. Virol. 66: 5110-5113.
21. Louis, J.M., Nesheiwat, I., Chang, L., Clore, G.M., and Bewley, C.A. 2003. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J. Biol. Chem. 278: 20278-20285.
22. Lu, M., Blacklow, S.C., and Kim, P.S. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2: 1075-1082.
23. McCaffrey, R.A., Saunders, C., Hensel, M., and Stamatatos, L. 2004. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J. Virol. 78: 3279-3295.
24. Melikyan, G.B., Markosyan, R.M., Hemmati, H., Delmedico, M.K., Lambert, D.M., and Cohen, F.S. 2000. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol. 151: 413-423.
25. Miller, M.D., Geleziunas, R., Bianchi, E., Lennard, S., Hrin, R., Zhang, H., Lu, M., An, Z., Ingallinella, P., Finotto, M., et al. 2005. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc. Natl. Acad. Sci. 102: 14759-14764.
26. Mirzabekov, T., Bannert, N., Farzan, M., Hofmann, W., Kolchinsky, P., Wu, L., Wyatt, R., and Sodroski, J. 1999. Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor. J. Biol. Chem. 274: 28745-28750.
27. Opalka, D., Pessi, A., Bianchi, E., Ciliberto, G., Schleif, W., McElhaugh, M., Danzeisen, R., Geleziunas, R., Miller, M., Eckert, D.M., et al. 2004. Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J. Immunol. Methods 287: 49-65.
28. Reeves, J.D., Gallo, S.A., Ahmad, N., Miamidian, J.L., Harvey, P.E., Sharron, M., Pohlmann, S., Sfakianos, J.N., Derdeyn, C.A., Blumenthal, R., et al. 2002. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. 99: 16249-16254.
29. Rimsky, L.T., Shugars, D.C., and Matthews, T.J. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72: 986-993.
30. Root, M.J., Kay, M.S., and Kim, P.S. 2001. Protein design of an HIV-1 entry inhibitor. Science 291: 884-888.
31. Saphire, E.O., Parren, P.W., Pantophlet, R., Zwick, M.B., Morris, G.M., Rudd, P.M., Dwek, R.A., Stanfield, R.L., Burton, D.R., and Wilson, I.A. 2001. Crystal structure of a neutralizing human IGG against HIV-1: A template for vaccine design. Science 293: 1155-1159.
32. Si, Z., Madani, N., Cox, J.M., Chruma, J.J., Klein, J.C., Schon, A., Phan, N., Wang, L., Biorn, A.C., Cocklin, S., et al. 2004. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Acad. Sci. 101: 5036-5041.
33. Tan, K., Liu, J., Wang, J., Shen, S., and Lu, M. 1997. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. 94: 12303-12308.
34. Varadarajan, R., Sharma, D., Chakraborty, K., Patel, M., Citron, M., Sinha, P., Yadav, R., Rashid, U., Kennedy, S., Eckert, D., et al. 2005. Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: Implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design. J. Virol. 79: 1713-1723.
35. Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar-Gonzalez, J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
36. Weiss, C.D. 2003. HIV-1 gp41: Mediator of fusion and target for inhibition. AIDS Rev. 5: 214-221.
37. Weissenhorn, W., Dessen, A., Harrison, S.C., Skehel, J.J., and Wiley, D.C. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
38. Welch, B.D., VanDemark, A.P., Heroux, A., Hill, C.P., and Kay, M.S. 2007. Potent D-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. 104: 16828-16833.
39. Wild, C., Oas, T., McDanal, C., Bolognesi, D., and Matthews, T. 1992. A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. 89: 10537-10541.
40. Wild, C., Greenwell, T., and Matthews, T. 1993. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 9: 1051-1053.
41. Wild, C.T., Shugars, D.C., Greenwell, T.K., McDanal, C.B., and Matthews, T.J. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. 91: 9770-9774.